Identification
NameLenalidomide
Accession NumberDB00480  (APRD01303)
TypeSmall Molecule
GroupsApproved
Description

Lenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. [Wikipedia] FDA approved on December 27, 2005.

Structure
Thumb
Synonyms
1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
CC-5013
CDC 501
IMid-1
IMiD3
Revlimid
External IDs Not Available
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RevlimidCapsule2.5 mgOralCelgene2016-12-20Not applicableCanada
RevlimidCapsule5 mgOralCelgene Europe Limited2007-06-14Not applicableEu
RevlimidCapsule20 mgOralCelgene Europe Limited2007-06-14Not applicableEu
RevlimidCapsule15 mg/1OralCelgene2006-06-29Not applicableUs
RevlimidCapsule10 mg/1OralCelgene2005-12-27Not applicableUs
RevlimidCapsule5 mgOralCelgene2008-02-19Not applicableCanada
RevlimidCapsule25 mgOralCelgene Europe Limited2007-06-14Not applicableEu
RevlimidCapsule2.5 mgOralCelgene Europe Limited2007-06-14Not applicableEu
RevlimidCapsule25 mgOralCelgene2008-10-10Not applicableCanada
RevlimidCapsule10 mgOralCelgene Europe Limited2007-06-14Not applicableEu
RevlimidCapsule2.5 mg/1OralCelgene2012-04-16Not applicableUs
RevlimidCapsule20 mg/1OralCelgene2013-06-06Not applicableUs
RevlimidCapsule10 mgOralCelgene2008-02-19Not applicableCanada
RevlimidCapsule2.5 mgOralCelgene Europe Limited2007-06-14Not applicableEu
RevlimidCapsule20 mgOralCelgene2015-09-28Not applicableCanada
RevlimidCapsule5 mgOralCelgene Europe Limited2007-06-14Not applicableEu
RevlimidCapsule25 mg/1OralCelgene2006-06-29Not applicableUs
RevlimidCapsule15 mgOralCelgene Europe Limited2007-06-14Not applicableEu
RevlimidCapsule5 mg/1OralCelgene2005-12-27Not applicableUs
RevlimidCapsule7.5 mgOralCelgene Europe Limited2007-06-14Not applicableEu
RevlimidCapsule15 mgOralCelgene2008-10-10Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LadevinaNot Available
Lenangio Not Available
Brand mixturesNot Available
Categories
UNIIF0P408N6V4
CAS number191732-72-6
WeightAverage: 259.2606
Monoisotopic: 259.095691297
Chemical FormulaC13H13N3O3
InChI KeyGOTYRUGSSMKFNF-UHFFFAOYSA-N
InChI
InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
IUPAC Name
3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
SMILES
NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Pharmacology
Indication

Lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Structured Indications
Pharmacodynamics

Lenalidomide, a thalidomide analogue, is an immunomodulatory agent possessing immunomodulatory and antiangiogenic properties. Lenalidomide inhibits the secretion of pro-inflammatory cytokines and increases the secretion of anti-inflammatory cytokines from peripheral blood mononuclear cells. Lenalidomide inhibits cell proliferation with varying effectiveness (IC50s) in some but not all cell lines. Lenalidomide is effective in inhibiting growth of Namalwa cells (a human B cell lymphoma cell line with a deletion of one chromosome 5) but is much less effective in inhibiting growth of KG-1 cells (human myeloblastic cell line, also with a deletion of one chromosome 5) and other cell lines without chromosome 5 deletions. Lenalidomide does not prolong the QTc interval.

Mechanism of action

The mechanism of action of lenalidomide remains to be fully characterized, however it has been demonstrated that lenalidomide inhibits the expression of cyclooxygenase-2 (COX-2), but not COX-1, in vitro. In vivo it induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity

TargetKindPharmacological actionActionsOrganismUniProt ID
Protein cereblonProteinyes
inhibitor
HumanQ96SW2 details
Tumor necrosis factor ligand superfamily member 11Proteinyes
inhibitor
HumanO14788 details
Cadherin-5Proteinunknown
antagonist
HumanP33151 details
Prostaglandin G/H synthase 2Proteinunknown
negative modulator
HumanP35354 details
Related Articles
Absorption

Rapidly absorbed following oral administration, with maximum plasma concentrations occurring between 0.625 and 1.5 hours post-dose. Co-administration with food does not alter the extent of absorption (AUC) but does reduce the maximal plasma concentration (Cmax) by 36%. The pharmacokinetic disposition of lenalidomide is linear. Accumulation does not occur following multiple doses.

Volume of distributionNot Available
Protein binding

30% protein bound.

Metabolism

Lenalidomide undergoes limited metabolism. Unchanged lenalidomide is the predominant circulating component in humans. Two identified metabolites are hydroxy-lenalidomide and N-acetyl-lenalidomide; each constitutes less than 5% of parent levels in circulation. The cytochrome P450 enzyme system is not involved with the metabolism of lenalidomide.

Route of elimination

Elimination is primarily renal. When a single oral dose of 25 mg is given healthy subjects, 90% and 4% of the dose is eliminated in urine and feces, respectively. Hydroxy-lenalidomide and N-acetyl-lenalidomide represent 4.59% and 1.83% of the excreted dose, respectively.

Half life

Healthy subjects = 3 hours; Multiple myeloma or MDS patients = 3 - 5 hours.

Clearance

The renal clearance of lenalidomide exceeds the glomerular filtration rate.

Toxicity

The most frequently reported adverse events were related to blood and lymphatic system disorders, skin and subcutaneous tissue disorders, gastrointestinal disorders, and general disorders and administrative site conditions.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetaminophenThe serum concentration of Lenalidomide can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Lenalidomide.Approved
AfatinibThe serum concentration of Lenalidomide can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Lenalidomide can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Lenalidomide can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Lenalidomide can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Lenalidomide can be increased when it is combined with Alfentanil.Approved, Illicit
AmantadineThe serum concentration of Lenalidomide can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Lenalidomide can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Lenalidomide can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Lenalidomide can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Lenalidomide can be increased when it is combined with Amlodipine.Approved
AmprenavirThe serum concentration of Lenalidomide can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Lenalidomide can be increased when it is combined with Amsacrine.Approved
AstemizoleThe serum concentration of Lenalidomide can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Lenalidomide can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Lenalidomide can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Lenalidomide can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Lenalidomide can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Lenalidomide can be increased when it is combined with Azithromycin.Approved
BazedoxifeneBazedoxifene may increase the thrombogenic activities of Lenalidomide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Lenalidomide.Investigational
BenzocaineThe serum concentration of Lenalidomide can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Lenalidomide can be increased when it is combined with Bepridil.Approved, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Lenalidomide.Approved, Investigational
BiperidenThe serum concentration of Lenalidomide can be increased when it is combined with Biperiden.Approved
BosutinibThe serum concentration of Lenalidomide can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Lenalidomide can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Lenalidomide can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Lenalidomide can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Lenalidomide.Approved
CaffeineThe serum concentration of Lenalidomide can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Lenalidomide can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Lenalidomide can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Lenalidomide can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Lenalidomide can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Lenalidomide can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Lenalidomide can be increased when it is combined with Caspofungin.Approved
ChloroquineThe serum concentration of Lenalidomide can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may increase the thrombogenic activities of Lenalidomide.Withdrawn
ChlorpromazineThe serum concentration of Lenalidomide can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Lenalidomide can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Lenalidomide can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Lenalidomide can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Lenalidomide can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Lenalidomide can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Lenalidomide can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Lenalidomide can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Lenalidomide can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Lenalidomide can be increased when it is combined with Clarithromycin.Approved
ClofazimineThe serum concentration of Lenalidomide can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Lenalidomide can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe serum concentration of Lenalidomide can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Clozapine.Approved
CobicistatThe serum concentration of Lenalidomide can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Lenalidomide can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Lenalidomide can be increased when it is combined with Colforsin.Experimental
Conjugated estrogensConjugated Equine Estrogens may increase the thrombogenic activities of Lenalidomide.Approved
CrizotinibThe serum concentration of Lenalidomide can be increased when it is combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Lenalidomide.Approved, Investigational
CyclosporineThe serum concentration of Lenalidomide can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
DaclatasvirThe serum concentration of Lenalidomide can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Lenalidomide can be increased when it is combined with Dactinomycin.Approved
Darbepoetin alfaDarbepoetin alfa may increase the thrombogenic activities of Lenalidomide.Approved, Investigational
DasatinibThe serum concentration of Lenalidomide can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Lenalidomide can be decreased when it is combined with Daunorubicin.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Lenalidomide.Approved
DesipramineThe serum concentration of Lenalidomide can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Lenalidomide.Approved
DesloratadineThe serum concentration of Lenalidomide can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneDexamethasone may increase the thrombogenic activities of Lenalidomide.Approved, Investigational, Vet Approved
DexamethasoneThe serum concentration of Lenalidomide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Lenalidomide can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Lenalidomide can be increased when it is combined with Diclofenac.Approved, Vet Approved
DienestrolDienestrol may increase the thrombogenic activities of Lenalidomide.Approved
DiethylstilbestrolDiethylstilbestrol may increase the thrombogenic activities of Lenalidomide.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Lenalidomide.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Lenalidomide.Approved
DihydroergotamineThe serum concentration of Lenalidomide can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Lenalidomide can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Lenalidomide can be increased when it is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lenalidomide.Approved, Investigational
DoxazosinThe serum concentration of Lenalidomide can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Lenalidomide can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Lenalidomide can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Lenalidomide can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Lenalidomide can be increased when it is combined with Dronedarone.Approved
ElbasvirThe serum concentration of Lenalidomide can be increased when it is combined with Elbasvir.Approved
EnalaprilThe serum concentration of Lenalidomide can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Lenalidomide can be increased when it is combined with Enzalutamide.Approved
EquolS Equol may increase the thrombogenic activities of Lenalidomide.Investigational
ErgonovineThe serum concentration of Lenalidomide can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Lenalidomide can be increased when it is combined with Ergotamine.Approved
ErythromycinThe serum concentration of Lenalidomide can be decreased when it is combined with Erythromycin.Approved, Vet Approved
ErythropoietinErythropoietin may increase the thrombogenic activities of Lenalidomide.Approved
EstradiolEstradiol may increase the thrombogenic activities of Lenalidomide.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Lenalidomide can be increased when it is combined with Estramustine.Approved
EstriolEstriol may increase the thrombogenic activities of Lenalidomide.Approved, Vet Approved
EstroneEstrone may increase the thrombogenic activities of Lenalidomide.Approved
Ethinyl EstradiolEthinyl Estradiol may increase the thrombogenic activities of Lenalidomide.Approved
EtoposideThe serum concentration of Lenalidomide can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Lenalidomide can be increased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Lenalidomide can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Lenalidomide can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Lenalidomide can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Lenalidomide can be increased when it is combined with Fidaxomicin.Approved
FingolimodLenalidomide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe serum concentration of Lenalidomide can be increased when it is combined with Fluconazole.Approved
FluoxetineThe serum concentration of Lenalidomide can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Lenalidomide can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Lenalidomide can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Lenalidomide can be increased when it is combined with Flurazepam.Approved, Illicit
FluvoxamineThe serum concentration of Lenalidomide can be increased when it is combined with Fluvoxamine.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Lenalidomide is combined with G17DT.Investigational
GefitinibThe serum concentration of Lenalidomide can be increased when it is combined with Gefitinib.Approved, Investigational
GenisteinGenistein may increase the thrombogenic activities of Lenalidomide.Investigational
GlyburideThe serum concentration of Lenalidomide can be increased when it is combined with Glyburide.Approved
Gramicidin DThe serum concentration of Lenalidomide can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Lenalidomide can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Lenalidomide can be increased when it is combined with Haloperidol.Approved
HexestrolHexestrol may increase the thrombogenic activities of Lenalidomide.Withdrawn
HydrocortisoneThe serum concentration of Lenalidomide can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
IdelalisibThe serum concentration of Lenalidomide can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Lenalidomide can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Lenalidomide can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Lenalidomide can be decreased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Lenalidomide can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Lenalidomide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Lenalidomide is combined with INGN 225.Investigational
IsavuconazoniumThe serum concentration of Lenalidomide can be increased when it is combined with Isavuconazonium.Approved, Investigational
ItraconazoleThe serum concentration of Lenalidomide can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Lenalidomide can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Lenalidomide can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Lenalidomide can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Lenalidomide can be increased when it is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Lenalidomide can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Lenalidomide can be increased when it is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Leflunomide.Approved, Investigational
LevofloxacinThe serum concentration of Lenalidomide can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Lenalidomide can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Lenalidomide can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Lenalidomide can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Lenalidomide can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Lenalidomide can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Lenalidomide can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Lenalidomide can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Lenalidomide can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Lenalidomide can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Lenalidomide can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Lenalidomide can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Lenalidomide can be decreased when it is combined with Lumacaftor.Approved
MaprotilineThe serum concentration of Lenalidomide can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Lenalidomide can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Lenalidomide can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Lenalidomide can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Lenalidomide can be increased when it is combined with Meprobamate.Approved, Illicit
MestranolMestranol may increase the thrombogenic activities of Lenalidomide.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Lenalidomide.Withdrawn
MethadoneThe serum concentration of Lenalidomide can be increased when it is combined with Methadone.Approved
MethallenestrilMethallenestril may increase the thrombogenic activities of Lenalidomide.Experimental
Methoxy polyethylene glycol-epoetin betaMethoxy polyethylene glycol-epoetin beta may increase the thrombogenic activities of Lenalidomide.Approved
MetoprololThe serum concentration of Lenalidomide can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Lenalidomide can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Lenalidomide can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Lenalidomide can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Lenalidomide can be decreased when it is combined with Mifepristone.Approved, Investigational
MitomycinThe serum concentration of Lenalidomide can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Lenalidomide can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MorphineThe serum concentration of Lenalidomide can be increased when it is combined with Morphine.Approved, Investigational
NaltrexoneThe serum concentration of Lenalidomide can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Lenalidomide can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Natalizumab.Approved, Investigational
NefazodoneThe serum concentration of Lenalidomide can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Lenalidomide can be decreased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Lenalidomide can be increased when it is combined with Neostigmine.Approved, Vet Approved
NicardipineThe serum concentration of Lenalidomide can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Lenalidomide can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Lenalidomide can be increased when it is combined with Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Lenalidomide can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Lenalidomide can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Lenalidomide can be increased when it is combined with Nitrendipine.Approved
NorethisteroneThe serum concentration of Lenalidomide can be decreased when it is combined with Norethisterone.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Lenalidomide.Experimental
OmeprazoleThe serum concentration of Lenalidomide can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Lenalidomide.Approved
P-NitrophenolThe serum concentration of Lenalidomide can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Lenalidomide.Approved, Vet Approved
Palmitic AcidThe serum concentration of Lenalidomide can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Lenalidomide can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Lenalidomide can be increased when it is combined with Paroxetine.Approved, Investigational
PerindoprilThe serum concentration of Lenalidomide can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe serum concentration of Lenalidomide can be decreased when it is combined with Phenobarbital.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Lenalidomide.Approved, Investigational
PimozideThe serum concentration of Lenalidomide can be increased when it is combined with Pimozide.Approved
Platelet Activating FactorThe serum concentration of Lenalidomide can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Lenalidomide can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Lenalidomide can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Lenalidomide can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Lenalidomide can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Lenalidomide can be increased when it is combined with Prednisone.Approved, Vet Approved
ProbenecidThe serum concentration of Lenalidomide can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Lenalidomide can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromestrienePromestriene may increase the thrombogenic activities of Lenalidomide.Investigational
PromethazineThe serum concentration of Lenalidomide can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Lenalidomide can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Lenalidomide can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Lenalidomide can be increased when it is combined with Protriptyline.Approved
QuercetinThe serum concentration of Lenalidomide can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Lenalidomide can be increased when it is combined with Quinacrine.Approved
QuinestrolQuinestrol may increase the thrombogenic activities of Lenalidomide.Approved
QuinidineThe serum concentration of Lenalidomide can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Lenalidomide can be increased when it is combined with Quinine.Approved
RanitidineThe serum concentration of Lenalidomide can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Lenalidomide can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Lenalidomide can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Lenalidomide can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Lenalidomide can be decreased when it is combined with Reserpine.Approved
RifampicinThe serum concentration of Lenalidomide can be decreased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Lenalidomide can be increased when it is combined with Rilpivirine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Lenalidomide is combined with CDX-110.Investigational
RitonavirThe serum concentration of Lenalidomide can be decreased when it is combined with Ritonavir.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Lenalidomide.Approved
RolapitantThe serum concentration of Lenalidomide can be increased when it is combined with Rolapitant.Approved
SaquinavirThe serum concentration of Lenalidomide can be decreased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Lenalidomide can be increased when it is combined with Scopolamine.Approved
SecoisolariciresinolSecoisolariciresinol may increase the thrombogenic activities of Lenalidomide.Investigational
SelegilineThe serum concentration of Lenalidomide can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Lenalidomide can be increased when it is combined with Sertraline.Approved
SimeprevirThe serum concentration of Lenalidomide can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Lenalidomide can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Lenalidomide.Approved
SirolimusThe serum concentration of Lenalidomide can be decreased when it is combined with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of Lenalidomide can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Lenalidomide can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Lenalidomide is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Lenalidomide can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Lenalidomide can be increased when it is combined with Staurosporine.Experimental
StreptozocinThe serum concentration of Lenalidomide can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Lenalidomide can be increased when it is combined with Sulfinpyrazone.Approved
SumatriptanThe serum concentration of Lenalidomide can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Lenalidomide can be increased when it is combined with Sunitinib.Approved, Investigational
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may increase the thrombogenic activities of Lenalidomide.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may increase the thrombogenic activities of Lenalidomide.Approved
TacrineThe serum concentration of Lenalidomide can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Lenalidomide.Approved, Investigational
TacrolimusThe serum concentration of Lenalidomide can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Lenalidomide can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Lenalidomide can be increased when it is combined with Taurocholic Acid.Experimental
TelmisartanThe serum concentration of Lenalidomide can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Lenalidomide can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Lenalidomide can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Lenalidomide can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Lenalidomide can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Lenalidomide can be increased when it is combined with Testosterone.Approved, Investigational
TiboloneTibolone may increase the thrombogenic activities of Lenalidomide.Approved
TicagrelorThe serum concentration of Lenalidomide can be increased when it is combined with Ticagrelor.Approved
TofacitinibLenalidomide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolvaptanThe serum concentration of Lenalidomide can be increased when it is combined with Tolvaptan.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Lenalidomide.Approved, Investigational
TrazodoneThe serum concentration of Lenalidomide can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Lenalidomide can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Lenalidomide can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Lenalidomide can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Lenalidomide can be increased when it is combined with Trimipramine.Approved
VenlafaxineThe serum concentration of Lenalidomide can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Lenalidomide can be decreased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Lenalidomide can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Lenalidomide can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Lenalidomide can be increased when it is combined with Vinorelbine.Approved, Investigational
ZimelidineThe serum concentration of Lenalidomide can be increased when it is combined with Zimelidine.Withdrawn
Food Interactions
  • When given with a fatty meal, the extent of absorption is reduced.
References
Synthesis Reference

Surya Narayana Devarakonda, Sesha Reddy Yarraguntla, Vamsi Krishna Mudapaka, Rajasekhar Kadaboina, Veerender Murki, Amarendhar Manda, Venkata Rao Badisa, Naresh Vemula, Rama Seshagiri Rao Pulla, Venu Nalivela, "PREPARATION OF LENALIDOMIDE." U.S. Patent US20110021567, issued January 27, 2011.

US20110021567
General References
  1. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb 10;352(6):549-57. [PubMed:15703420 ]
  2. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006 Jul 15;108(2):618-21. Epub 2006 Mar 28. [PubMed:16569772 ]
  3. Anderson KC: Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8. [PubMed:16344099 ]
External Links
ATC CodesL04AX04 — Lenalidomide
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (400 KB)
MSDSDownload (225 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingBasic SciencePlasma Cell Myeloma1
0TerminatedTreatmentAdult T-cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease / Leukemia, Adult T-Cell / Peripheral T-Cell Lymphoma (PTCL) / Peripheral T-cell Lymphoma Unspecified / T/Null Cell Systemic Type1
0TerminatedTreatmentMultiple Myeloma (MM)1
0Unknown StatusTreatmentMyelodysplasia1
1Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Lymphocytic Leukaemia (CLL)1
1Active Not RecruitingTreatmentAcute Myelocytic Leukemia / Acute Myelogenous Leukaemia (AML) / Acute Myeloid Leukaemias (AML) / Acute Non-Lymphocytic Leukemia1
1Active Not RecruitingTreatmentAdenoidcystic Carcinoma / Neuroendocrine Tumors / Solid Organ Malignancies1
1Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With PML-RARA / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Alkylating Agent-Related Acute Myeloid Leukemia / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Leukemia, Prolymphocytic / Lymphomatous Involvement of Non-Cutaneous Extranodal Site / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Nodal Marginal Zone Lymphoma / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides and Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Richter's Syndrome / Small Intestinal Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1Active Not RecruitingTreatmentAdvanced Cancers1
1Active Not RecruitingTreatmentAnaplastic Astrocytoma (AA) / Diffuse Intrinsic Pontine Glioma (DIPG) / High Grade Glioma (HGG)1
1Active Not RecruitingTreatmentB Chronic Lymphocytic Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
1Active Not RecruitingTreatmentCD20 Positive / Stage II Grade 1 Contiguous Follicular Lymphoma / Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Stage II Grade 2 Contiguous Follicular Lymphoma / Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma1
1Active Not RecruitingTreatmentCancer of the Urethra / Ureteral Cancer / Urethral Cancer / Urethral Neoplasms1
1Active Not RecruitingTreatmentExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue / Nodal Marginal Zone Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1Active Not RecruitingTreatmentHodgkins Disease (HD)1
1Active Not RecruitingTreatmentLeukaemia, Acute1
1Active Not RecruitingTreatmentLeukemia Lymphocytic Chronic B-Cell1
1Active Not RecruitingTreatmentLeukemias1
1Active Not RecruitingTreatmentLymphoma, Hodgkins1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)1
1Active Not RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
1Active Not RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
1Active Not RecruitingTreatmentMultiple Myeloma in Relapse1
1Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1Active Not RecruitingTreatmentPlasma Cell Myeloma1
1Active Not RecruitingTreatmentRecurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Small Lymphocytic Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma1
1Active Not RecruitingTreatmentRecurrent Colon Carcinoma / Recurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Laryngeal Verrucous Carcinoma / Recurrent Lip and Oral Cavity Squamous Cell Carcinoma / Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary / Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Recurrent Oral Cavity Verrucous Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Recurrent Rectal Carcinoma / Recurrent Salivary Gland Carcinoma / Salivary Gland Squamous Cell Carcinoma / Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma / Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 / Stage IVA Colon Cancer / Stage IVA Colon Cancer AJCC v7 / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Laryngeal Verrucous Carcinoma / Stage IVA Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVA Major Salivary Gland Cancer AJCC v7 / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVA Oral Cavity Verrucous Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Rectal Cancer / Stage IVA Rectal Cancer AJCC v7 / Stage IVB Colon Cancer / Stage IVB Colon Cancer AJCC v7 / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Laryngeal Verrucous Carcinoma / Stage IVB Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVB Major Salivary Gland Cancer AJCC v7 / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVB Oral Cavity Verrucous Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Rectal Cancer / Stage IVB Rectal Cancer AJCC v7 / Stage IVC Laryngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVC Laryngeal Verrucous Carcinoma / Stage IVC Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVC Major Salivary Gland Cancer AJCC v7 / Stage IVC Major Salivary Gland Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVC Oral Cavity Verrucous Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Tongue Carcinoma / Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary1
1Active Not RecruitingTreatmentRecurrent Follicular Lymphoma1
1Active Not RecruitingTreatmentRefractory/Relapsed Indolent Non-Hodgkin Lymphoma1
1Active Not RecruitingTreatmentRelapsed/Refractory B-cell Lymphoma1
1CompletedNot AvailableHealthy Volunteers2
1CompletedTreatmentAcute Myelogenous Leukaemia (AML)1
1CompletedTreatmentAcute Myeloid Leukaemias (AML) / Bone Marrow Diseases / Chronic Myelomonocytic Leukemia / Myeldysplastic Syndrome (MDS) / Neutropenias1
1CompletedTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Alkylating Agent-Related Acute Myeloid Leukemia / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult T-cell lymphomas/leukaemias / Peripheral T-Cell Lymphoma (PTCL)1
1CompletedTreatmentAdvanced Cancer, Various, NOS1
1CompletedTreatmentAdvanced Cancers1
1CompletedTreatmentAnemias / Chronic Lymphocytic Leukaemia (CLL) / Leukemia, Prolymphocytic / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Thrombocytopenias1
1CompletedTreatmentBrain and Central Nervous System Tumors1
1CompletedTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor / Childhood Central Nervous System Germ Cell Tumor / Childhood Choroid Plexus Tumor / Childhood Craniopharyngioma / Childhood Ependymoblastoma / Childhood Grade I Meningioma / Childhood Grade II Meningioma / Childhood Grade III Meningioma / Childhood High-grade Cerebellar Astrocytoma / Childhood High-grade Cerebral Astrocytoma / Childhood Infratentorial Ependymoma / Childhood Low-grade Cerebellar Astrocytoma / Childhood Low-grade Cerebral Astrocytoma / Childhood Medulloepithelioma / Childhood Mixed Glioma / Childhood Oligodendroglioma / Childhood Supratentorial Ependymoma / Recurrent Childhood Brain Tumor / Recurrent Childhood Cerebellar Astrocytoma / Recurrent Childhood Cerebral Astrocytoma / Recurrent Childhood Ependymoma / Recurrent Childhood Medulloblastoma / Recurrent Childhood Pineoblastoma / Recurrent Childhood Subependymal Giant Cell Astrocytoma / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Childhood Visual Pathway and Hypothalamic Glioma1
1CompletedTreatmentChildhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ringed Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Secondary Myelodysplastic Syndromes / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Indolent Non-Hodgkin's Lymphomas / Mantle Cell Lymphoma (MCL)1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, B-Cell, Chronic1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentHealthy, Male1
1CompletedTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
1CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMalignant Melanoma1
1CompletedTreatmentMalignant Neoplasm of Prostate1
1CompletedTreatmentMelanoma1
1CompletedTreatmentMultiple Myeloma (MM)11
1CompletedTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma / Relapsed Multiple Myeloma1
1CompletedTreatmentMyelodysplasia1
1CompletedTreatmentMyelodysplastic Syndrome1
1CompletedTreatmentMyelodysplastic Syndromes1
1CompletedTreatmentMyelodysplastic Syndromes (MDS)1
1CompletedTreatmentNeoplasms1
1CompletedTreatmentPlasma Cell Myeloma2
1CompletedTreatmentRefractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1CompletedTreatmentRelapsed Multiple Myeloma1
1CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
1CompletedTreatmentSmoldering Multiple Myeloma (SMM)1
1CompletedTreatmentTumors, Solid1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1Not Yet RecruitingTreatmentBurkitt's Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
1Not Yet RecruitingTreatmentCLL / Richter's Syndrome1
1Not Yet RecruitingTreatmentHypercalcemia / Plasmacytoma / Recurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1Not Yet RecruitingTreatmentNeuroblastomas1
1RecruitingPreventionSmoldering Multiple Myeloma (SMM)1
1RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
1RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome2
1RecruitingTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
1RecruitingTreatmentAutoimmune Pancreatitis / IgG4-related Disease / IgG4-related Sclerosing Cholangitis / Immunoglobulin G Subclass 4 Related Disease / Retroperitoneal Fibrosis1
1RecruitingTreatmentB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Grade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Grade 3a Follicular Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Refractory Burkitt Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Transformed Recurrent Non-Hodgkin Lymphoma1
1RecruitingTreatmentB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma / CD19 Positive / Mediastinal Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma1
1RecruitingTreatmentB-Cell Prolymphocytic Leukemia / Leukemia, Prolymphocytic / Recurrent Chronic Lymphocytic Leukemia / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Small Lymphocytic Lymphoma1
1RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
1RecruitingTreatmentFollicular Lymphoma (FL)1
1RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL) / Primary Mediastinal B-Cell Lymphoma1
1RecruitingTreatmentHaematological Malignancies / Plasma Cell Myeloma1
1RecruitingTreatmentIntraocular Lymphoma / Recurrent/Refractory CNS1
1RecruitingTreatmentLeukemias1
1RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1RecruitingTreatmentMantle Cell Lymphoma (MCL)1
1RecruitingTreatmentMultiple Myeloma (MM)8
1RecruitingTreatmentMyelodysplastic Syndromes / Myeloid Leukemias1
1RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1RecruitingTreatmentPartial Response of Multiple Myeloma or Plasma Cell Leukemia / Plasma Cell Myeloma1
1RecruitingTreatmentRecurrent Neuroblastoma / Stage 4 Neuroblastoma1
1RecruitingTreatmentTumors, Central Nervous System1
1RecruitingTreatmentTumors, Solid1
1TerminatedTreatmentAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndromes1
1TerminatedTreatmentAcute Myeloid Leukaemias (AML)1
1TerminatedTreatmentAdult Grade III Lymphomatoid Granulomatosis / Adult Non-Hodgkin's Lymphoma / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1TerminatedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1TerminatedTreatmentAdvanced Cancers1
1TerminatedTreatmentB-Cell Chronic Lymphocytic Leukemia1
1TerminatedTreatmentCancer, Ovarian / Fallopian Tube Carcinoma / Ovarian Epithelial Cancer / Primary Peritoneal Carcinoma1
1TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, Lymphocytic, Chronic, B-Cell / Small Lymphocytic Lymphoma (SLL)1
1TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemia, Small Lymphocytic1
1TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)1
1TerminatedTreatmentHepatocellular,Carcinoma1
1TerminatedTreatmentMalignant Gliomas1
1TerminatedTreatmentMalignant Lymphomas / Multiple Myeloma (MM)1
1TerminatedTreatmentMalignant Neoplasm of Colon / Rectal Carcinoma1
1TerminatedTreatmentMalignant Neoplasm of Prostate1
1TerminatedTreatmentMultiple Myeloma (MM)1
1TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1TerminatedTreatmentPlasma Cell Myeloma1
1TerminatedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1Unknown StatusTreatmentAdvanced Solid Tumors1
1, 2Active Not RecruitingTreatmentAIDS-Related Hodgkin Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent T-Cell Non-Hodgkin Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome1
1, 2Active Not RecruitingTreatmentAdult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Progressive Hairy Cell Leukemia, Initial Treatment / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage 0 Chronic Lymphocytic Leukemia / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Untreated Hairy Cell Leukemia / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentChronic Myelomonocytic Leukemia1
1, 2Active Not RecruitingTreatmentDiffuse Large B Cell Lymphoma Refractory / Diffuse Large B Cell Lymphoma Relapsed1
1, 2Active Not RecruitingTreatmentIndolent Plasma Cell Myeloma / Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas2
1, 2Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)10
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
1, 2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentPlasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma1
1, 2Active Not RecruitingTreatmentRecurrent Thyroid Gland Carcinoma / Stage I Thyroid Gland Follicular Carcinoma / Stage I Thyroid Gland Papillary Carcinoma / Stage II Thyroid Gland Follicular Carcinoma / Stage II Thyroid Gland Papillary Carcinoma / Stage III Thyroid Gland Follicular Carcinoma / Stage III Thyroid Gland Papillary Carcinoma / Stage IV Thyroid Gland Follicular Carcinoma / Stage IV Thyroid Gland Papillary Carcinoma / Stage IVA Thyroid Gland Follicular Carcinoma / Stage IVA Thyroid Gland Papillary Carcinoma / Stage IVB Thyroid Gland Follicular Carcinoma / Stage IVB Thyroid Gland Papillary Carcinoma / Stage IVC Thyroid Gland Follicular Carcinoma / Stage IVC Thyroid Gland Papillary Carcinoma1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma2
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma / Smoldering Multiple Myeloma (SMM) / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1, 2Active Not RecruitingTreatmentRelapsed or Refractory / Relapsed or Refractory B- / T-Cell Lymphomas1
1, 2Active Not RecruitingTreatmentRelapsed/Refractory Mantle Cell Lymphoma1
1, 2CompletedNot AvailableCancer, Ovarian1
1, 2CompletedNot AvailableChronic Lymphocytic Leukaemia (CLL)1
1, 2CompletedTreatmentAcute Myeloid Leukaemias (AML) / Adult Acute Myeloblastic Leukemia1
1, 2CompletedTreatmentAmyloidosis1
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / CLL1
1, 2CompletedTreatmentCarcinoma, Pancreatic1
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)4
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, B-Cell / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL) / Waldenstrom's Macroglobulinemia (WM)1
1, 2CompletedTreatmentKaposi's Sarcoma AIDS Related / Recurrent Kaposi's Sarcoma1
1, 2CompletedTreatmentLeukemia, Lymphocytic, Chronic, B-Cell1
1, 2CompletedTreatmentLeukemia, Myeloid, Acute1
1, 2CompletedTreatmentLeukemias1
1, 2CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
1, 2CompletedTreatmentLow- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)1
1, 2CompletedTreatmentMalignancies, Hematologic / Multiple Myeloma (MM)1
1, 2CompletedTreatmentMalignant Lymphomas2
1, 2CompletedTreatmentMalignant Neoplasm of Prostate2
1, 2CompletedTreatmentMantle Cell Lymphoma (MCL)1
1, 2CompletedTreatmentMultiple Myeloma (MM)7
1, 2CompletedTreatmentPlasma Cell Myeloma1
1, 2CompletedTreatmentPlasma Cell Myeloma / Transplantation, Stem Cell1
1, 2CompletedTreatmentRecurrent Ovarian Cancer1
1, 2CompletedTreatmentRefractory Multiple Myeloma / Relapses1
1, 2CompletedTreatmentWaldenstrom's Macroglobulinemia (WM)1
1, 2Not Yet RecruitingTreatmentLymphoma, B Cell / Malignant Lymphomas1
1, 2RecruitingTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Recurrent Adult Acute Myeloid Leukemia1
1, 2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage II Angioimmunoblastic T-cell Lymphoma / Stage II Enteropathy-Associated T-Cell Lymphoma / Stage III Angioimmunoblastic T-cell Lymphoma / Stage III Enteropathy-Associated T-Cell Lymphoma / Stage IV Angioimmunoblastic T-cell Lymphoma / Stage IV Enteropathy-Associated T-Cell Lymphoma1
1, 2RecruitingTreatmentCD20 Positive / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Transformed Recurrent Non-Hodgkin Lymphoma1
1, 2RecruitingTreatmentCancer, Advanced1
1, 2RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Multiple Myeloma (MM) / Plasma Cell Myeloma1
1, 2RecruitingTreatmentFollicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II) / Follicular Lymphoma Patients (Phase IB)1
1, 2RecruitingTreatmentFolliculotropic Mycosis Fungoides / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides / Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma / Refractory Mycosis Fungoides / Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified / Sezary Syndrome1
1, 2RecruitingTreatmentGrade 3a Follicular Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Follicular Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Waldenstrom Macroglobulinemia / Refractory Burkitt Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Follicular Lymphoma / Refractory Lymphoplasmacytic Lymphoma / Refractory Mantle Cell Lymphoma1
1, 2RecruitingTreatmentLeukemia, Lymphocytic, Chronic, B-Cell / Malignant Lymphomas1
1, 2RecruitingTreatmentLymphoma, B-Cell1
1, 2RecruitingTreatmentLymphoma, B-Cell / Primary Effusion Lymphomas1
1, 2RecruitingTreatmentMalignant Lymphomas4
1, 2RecruitingTreatmentMultiple Myeloma (MM)6
1, 2RecruitingTreatmentNonsmall Cell Lung Cancer / Relapsed or Refractory Solid Tumors1
1, 2RecruitingTreatmentPlasma Cell Leukemia in Remission / Plasma Cell Myeloma1
1, 2RecruitingTreatmentPlasma Cell Myeloma1
1, 2RecruitingTreatmentRecurrent Chronic Lymphocytic Leukemia1
1, 2RecruitingTreatmentRecurrent Plasma Cell Myeloma1
1, 2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2RecruitingTreatmentRefractory Diffuse Large B-Cell Lymphoma / Relapsed Diffuse Large B-Cell Lymphoma1
1, 2RecruitingTreatmentRelapsed Hodgkin Lymphoma / Relapsed Non-Hodgkin's Lymphoma1
1, 2RecruitingTreatmentRelapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma1
1, 2TerminatedTreatmentAggressive Marginal Zone Lymphoma (MZL) / Burkitt Lymphoma (BL) / Follicular Lymphoma Grade III (FL III°) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL), Blastoid Variant1
1, 2TerminatedTreatmentCancer, Ovarian1
1, 2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1, 2TerminatedTreatmentLow to Intermediate-1 MDS / Myelodysplastic Syndrome / Non-deletion 5q / Smith-Magenis Syndrome1
1, 2TerminatedTreatmentLymphoma, Hodgkins / Mature T-cell Lymphoma / Multiple Myeloma (MM)1
1, 2TerminatedTreatmentMalignant Neoplasm of Pancreas1
1, 2TerminatedTreatmentMultiple Myeloma (MM)1
1, 2TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
1, 2TerminatedTreatmentPeripheral T-Cell Non-Hodgkin's Lymphoma1
1, 2TerminatedTreatmentRelapsed Or Refractory Multiple Myeloma1
1, 2TerminatedTreatmentRenal Cell Adenocarcinoma1
1, 2TerminatedTreatmentUrinary Bladder Neoplasms1
1, 2Unknown StatusTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer1
1, 2Unknown StatusTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Unknown StatusTreatmentAmyloidosis1
1, 2Unknown StatusTreatmentCancer Cachexia Syndrome1
1, 2Unknown StatusTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
1, 2Unknown StatusTreatmentFollicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone B-Cell Lymphoma1
1, 2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2Unknown StatusTreatmentMultiple Myeloma (MM)4
1, 2Unknown StatusTreatmentTumors, Solid1
1, 2WithdrawnTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2WithdrawnTreatmentFollicular Lymphoma (FL) / Malignant Lymphomas1
1, 2WithdrawnTreatmentMultiple Myeloma (MM)2
2Active Not RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / Acute Myeloid Leukaemias (AML)1
2Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome1
2Active Not RecruitingTreatmentAdult Lymphocyte Depletion Hodgkin Lymphoma / Adult Lymphocyte Predominant Hodgkin Lymphoma / Adult Mixed Cellularity Hodgkin Lymphoma / Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma / Adult Nodular Sclerosis Hodgkin Lymphoma / Recurrent Adult Hodgkin's Lymphoma1
2Active Not RecruitingTreatmentAdult Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia / Chronic Myelomonocytic Leukemia-1 / Chronic Myelomonocytic Leukemia-2 / Previously Treated Myelodysplastic Syndromes / Refractory Anemia With Excess Blasts1
2Active Not RecruitingTreatmentAdult T-cell lymphomas/leukaemias1
2Active Not RecruitingTreatmentAdvanced Myeloma / Plasma Cell Myeloma1
2Active Not RecruitingTreatmentAgnogenic Myeloid Metaplasia1
2Active Not RecruitingTreatmentBladder Cancers1
2Active Not RecruitingTreatmentCD20 Positive / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / CLL1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)2
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)3
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Stage 0 Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma1
2Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2Active Not RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma of Mucosa-Associated Lymphoid Tissue / Lymphoma, Mantle-Cell / MALT Lymphoma / Marginal Zone B-Cell Lymphoma / Small Lymphocytic Lymphoma (SLL) / Waldenstrom's Macroglobulinemia (WM)1
2Active Not RecruitingTreatmentLenalidomide / Malignant Lymphomas / Relapses / Rituximab1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas2
2Active Not RecruitingTreatmentLymphoma, Mantle-Cell / Mantle Cell Lymphoma (MCL)1
2Active Not RecruitingTreatmentMalignant Lymphomas4
2Active Not RecruitingTreatmentMalignant Neoplasm of Prostate1
2Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)3
2Active Not RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)22
2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Renal Failure1
2Active Not RecruitingTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2Active Not RecruitingTreatmentMyelodysplastic Syndrome3
2Active Not RecruitingTreatmentMyelodysplastic Syndromes2
2Active Not RecruitingTreatmentMyelodysplastic Syndrome / Smith-Magenis Syndrome1
2Active Not RecruitingTreatmentMyeloproliferative Diseases1
2Active Not RecruitingTreatmentNeoplasms, Thyroid1
2Active Not RecruitingTreatmentNeurofibromatosis Type 1 / Recurrent Childhood Pilocytic Astrocytoma / Recurrent Childhood Visual Pathway Glioma1
2Active Not RecruitingTreatmentNewly Diagnosed Multiple Myeloma1
2Active Not RecruitingTreatmentNon Hodgkin Lymphoma (NHL)1
2Active Not RecruitingTreatmentPlasma Cell Myeloma2
2Active Not RecruitingTreatmentRecurrent Mantle Cell Lymphoma1
2Active Not RecruitingTreatmentRelapsed or Refractory Chronic Lymphocytic Leukemia1
2Active Not RecruitingTreatmentSmoldering Multiple Myeloma (SMM) / Smoldering Myeloma1
2Active Not RecruitingTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma2
2Active Not RecruitingTreatmentStage II Grade 1 Contiguous Follicular Lymphoma / Stage II Grade 1 Non-Contiguous Follicular Lymphoma / Stage II Grade 2 Contiguous Follicular Lymphoma / Stage II Grade 2 Non-Contiguous Follicular Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma1
2CompletedNot AvailableImpaired Renal Function / Multiple Myeloma (MM)1
2CompletedNot AvailablePlasma Cell Dyscrasia1
2CompletedTreatmentAML / Smith-Magenis Syndrome1
2CompletedTreatmentAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome1
2CompletedTreatmentAcute Myeloid Leukaemias (AML)3
2CompletedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2CompletedTreatmentAdult T Cell Leukemia/Lymphoma1
2CompletedTreatmentAgnogenic Myeloid Metaplasia1
2CompletedTreatmentAmyloidosis2
2CompletedTreatmentAngiogenesis / Leukemia, Myelomonocytic, Chronic / Myelodysplastic Syndromes1
2CompletedTreatmentAutism, Early Infantile1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / CLL / Leukemias / Small Lymphocytic Lymphoma (SLL)1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)5
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias2
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL)3
2CompletedTreatmentComplex Regional Pain Syndrome (RSD)1
2CompletedTreatmentCrohn's Disease (CD)1
2CompletedTreatmentEssential Thrombocythemia (ET) / Polycythemia Vera (PV) / Primary Myelofibrosis1
2CompletedTreatmentFollicular Lymphoma (FL)1
2CompletedTreatmentGlioblastomas / Gliosarcoma / Malignant Gliomas1
2CompletedTreatmentHematologic Cancers1
2CompletedTreatmentHodgkins Disease (HD)2
2CompletedTreatmentLeukemia, Lymphocytic / Mantle Cell Lymphoma (MCL)1
2CompletedTreatmentLeukemia, Myeloid, Acute1
2CompletedTreatmentLeukemias1
2CompletedTreatmentLiver Cancer2
2CompletedTreatmentLymphoma of the Mucosa Associated Lymphoid Tissue (MALT)1
2CompletedTreatmentMalignant Lymphomas3
2CompletedTreatmentMalignant Neoplasm of Prostate1
2CompletedTreatmentMantle Cell Lymphoma (MCL)1
2CompletedTreatmentMelanoma1
2CompletedTreatmentMultiple Myeloma (MM)24
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm4
2CompletedTreatmentMyelodysplastic Syndrome2
2CompletedTreatmentMyelodysplastic Syndromes6
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)3
2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentPOEMS Syndrome2
2CompletedTreatmentPancreatic Cancer Metastatic1
2CompletedTreatmentPrimary Plasma Cell Leukemia1
2CompletedTreatmentPrimary Systemic Amyloidosis1
2CompletedTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2CompletedTreatmentRefractory Primary-cutaneous Large B-cell Lymphoma (Leg-type)1
2CompletedTreatmentRenal Cancers2
2CompletedTreatmentSquamous Cell Carcinoma (SCC)1
2CompletedTreatmentT-Cell Lymphomas1
2CompletedTreatmentLight chain amyloidosis1
2Not Yet RecruitingTreatmentAML1
2Not Yet RecruitingTreatmentB-cell Non-Hodgkin's Lymphomas1
2Not Yet RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
2Not Yet RecruitingTreatmentEBV Related Non-Hodgkin's Lymphoma / Primary CNS Lymphoma / Primary Testicular Lymphoma1
2Not Yet RecruitingTreatmentMucosa Associated Lymphoid Tissue (MALT) Lymphoma1
2Not Yet RecruitingTreatmentMultiple Myeloma (MM)4
2Not Yet RecruitingTreatmentPlasma Cell Myeloma1
2RecruitingSupportive CareMultiple Myeloma (MM)1
2RecruitingTreatmentAdult Myelodysplastic Syndrome / Anemias / Chronic Myelomonocytic Leukemia1
2RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IA Mycosis Fungoides/Sezary Syndrome / Stage IB Mycosis Fungoides/Sezary Syndrome / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IIA Mycosis Fungoides/Sezary Syndrome / Stage IIB Mycosis Fungoides/Sezary Syndrome / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IIIA Mycosis Fungoides/Sezary Syndrome / Stage IIIB Mycosis Fungoides/Sezary Syndrome / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IVA Mycosis Fungoides/Sezary Syndrome / Stage IVB Mycosis Fungoides/Sezary Syndrome1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)2
2RecruitingTreatmentContiguous Stage II Small Lymphocytic Lymphoma / Leukemia, Prolymphocytic / Noncontiguous Stage II Small Lymphocytic Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage III Small Lymphocytic Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Small Lymphocytic Lymphoma1
2RecruitingTreatmentFollicular Lymphoma (FL)1
2RecruitingTreatmentFollicular Lymphoma (FL) / Malignant Lymphomas1
2RecruitingTreatmentHistiocytic Sarcoma (HS) / Histiocytoses Erdheim-chester Disease / Langerhans Cell Histiocytosis (LCH)1
2RecruitingTreatmentLeukemia, Myeloid, Acute / Leukemia, Myelomonocytic, Chronic / Myelodysplastic Syndromes1
2RecruitingTreatmentLeukemias2
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2RecruitingTreatmentMalignant Lymphomas1
2RecruitingTreatmentMalignant Lymphomas / Neurotoxicity / Therapy-Related Toxicity1
2RecruitingTreatmentMantle Cell Lymphoma (MCL) / Untreated1
2RecruitingTreatmentMonoclonal B-Cell Lymphocytosis / Stage 0 Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage I Small Lymphocytic Lymphoma1
2RecruitingTreatmentMultiple Myeloma (MM)13
2RecruitingTreatmentMyelodysplastic Syndromes1
2RecruitingTreatmentMyeloid Leukemias1
2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentPOEMS Syndrome1
2RecruitingTreatmentPlasmacytoma / POEMS Syndrome1
2RecruitingTreatmentPlasma Cell Myeloma2
2RecruitingTreatmentPlasma Cell Myeloma / Residual Disease1
2RecruitingTreatmentPlasma Cell Myeloma / Transplant-Related Carcinoma1
2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Multiple Myeloma / Refractory Plasma Cell Myeloma1
2RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2RecruitingTreatmentRelapse/Refractory Multiple Myeloma1
2RecruitingTreatmentRelapsed/Refractory Mantle Cell Lymphoma1
2RecruitingTreatmentSmith-Magenis Syndrome1
2RecruitingTreatmentSmoldering Multiple Myeloma (SMM)2
2RecruitingTreatmentSmoldering Multiple Myeloma (SMM) / Smoldering Multiple Myeloma at High Risk of Progression to Symptomatic Multiple Myeloma1
2RecruitingTreatmentT-Cell Lymphomas1
2SuspendedSupportive CareNeuropathy / Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)1
2TerminatedOtherHaematological disorders1
2TerminatedTreatmentAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndromes1
2TerminatedTreatmentAcute Myeloid Leukaemias (AML) / Leukemias / Myelodysplastic Syndromes (MDS)1
2TerminatedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Leukemia, Prolymphocytic / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2TerminatedTreatmentCancer, Advanced / Pain1
2TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL)4
2TerminatedTreatmentChronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)1
2TerminatedTreatmentColorectal Cancers1
2TerminatedTreatmentComplex Regional Pain Syndrome, Type I1
2TerminatedTreatmentFollicular Lymphoma (FL) / Marginal Zone Lymphoma1
2TerminatedTreatmentGraft Versus Host Disease (GVHD)1
2TerminatedTreatmentHIV Infection Associated Kaposi Disease1
2TerminatedTreatmentIntraocular Melanoma / Malignant Conjunctival Neoplasm1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentLeukemias / Relapsed Adult Acute Lymphocytic Leukemia1
2TerminatedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2TerminatedTreatmentMultiple Myeloma (MM)3
2TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2TerminatedTreatmentMyelodysplastic Syndrome MDS1
2TerminatedTreatmentPeripheral T-Cell Lymphoma (PTCL)1
2TerminatedTreatmentRefractory Plasma Cell Myeloma1
2TerminatedTreatmentSmith-Magenis Syndrome1
2TerminatedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2TerminatedTreatmentT-Cell Non-Hodgkin Lymphoma1
2TerminatedTreatmentWaldenstrom's Macroglobulinemia (WM)2
2Unknown StatusTreatmentAcute Myelogenous Leukaemia (AML) / Myelodysplastic Syndrome1
2Unknown StatusTreatmentChronic Lymphocytic Leukaemia (CLL) / CLL / First-Line / Front-line / Initial Therapy / Untreated1
2Unknown StatusTreatmentChronic Lymphocytic Leukaemia (CLL) / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia1
2Unknown StatusTreatmentCutaneous T Cell Lymphomas (CTCL)1
2Unknown StatusTreatmentIndolent Non Hodgkin Lymphoma1
2Unknown StatusTreatmentLeukemia, Lymphocytic / Precursor B-Cell Lymphoblastic Leukemia-Lymphoma1
2Unknown StatusTreatmentLeukemias1
2Unknown StatusTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2Unknown StatusTreatmentMALT Lymphoma1
2Unknown StatusTreatmentMalignant Lymphomas2
2Unknown StatusTreatmentMultiple Myeloma (MM)3
2Unknown StatusTreatmentMyelodysplastic Syndrome1
2Unknown StatusTreatmentMyelodysplastic Syndromes1
2Unknown StatusTreatmentPOEMS Syndrome1
2Unknown StatusTreatmentRefractory Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2WithdrawnTreatmentChronic Lymphocytic Leukaemia (CLL)1
2WithdrawnTreatmentChronic Lymphocytic Leukaemia (CLL) / Stage III Chronic Lymphocytic Leukemia / Stage IV Chronic Lymphocytic Leukemia1
2WithdrawnTreatmentLeukemias / Malignant Lymphomas1
2WithdrawnTreatmentMalignant Gliomas1
2WithdrawnTreatmentMultiple Myeloma (MM)3
2WithdrawnTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2, 3Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2, 3CompletedTreatmentRadicular syndrome1
2, 3RecruitingTreatmentMultiple Myeloma (MM)2
3Active Not RecruitingBasic ScienceNewly Diagnosed, Previously Untreated Multiple Myeloma1
3Active Not RecruitingTreatmentAnemias1
3Active Not RecruitingTreatmentAnemias / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes1
3Active Not RecruitingTreatmentB-Cell Chronic Lymphocytic Leukemia1
3Active Not RecruitingTreatmentB-Cell Chronic Lymphocytic Leukemia (B-CLL)1
3Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma1
3Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Refractory Plasma Cell Myeloma / Smoldering Plasma Cell Myeloma1
3Active Not RecruitingTreatmentDS Stage I Plasma Cell Myeloma / DS Stage II Plasma Cell Myeloma / DS Stage III Plasma Cell Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3Active Not RecruitingTreatmentFollicular Lymphoma (FL)2
3Active Not RecruitingTreatmentLight Chain Deposition Disease / Smoldering Plasma Cell Myeloma1
3Active Not RecruitingTreatmentLymphoma (Myeloma) / Multiple Myeloma (MM)1
3Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Malignant Lymphomas1
3Active Not RecruitingTreatmentMantle Cell Lymphoma (MCL)1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)9
3Active Not RecruitingTreatmentMultiple Myeloma (MM) / Newly Diagnosed Patients1
3Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3Active Not RecruitingTreatmentPlasma Cell Myeloma2
3Active Not RecruitingTreatmentPreviously Untreated Symptomatic Multiple Myeloma1
3Active Not RecruitingTreatmentRefractory Multiple Myeloma / Relapsed Multiple Myeloma1
3Active Not RecruitingTreatmentRelapsed Multiple Myeloma1
3Active Not RecruitingTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3CompletedDiagnosticMultiple Myeloma (MM)1
3CompletedPreventionMelanoma / Neoplasms Metastasis1
3CompletedTreatmentMalignant Neoplasm of Prostate1
3CompletedTreatmentMultiple Myeloma (MM)10
3CompletedTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
3CompletedTreatmentMyelodysplastic Syndromes1
3CompletedTreatmentNewly Diagnosed Multiple Myeloma1
3CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
3Not Yet RecruitingTreatmentPlasmacytoma1
3RecruitingTreatmentFollicular Lymphoma (FL)1
3RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
3RecruitingTreatmentMantle Cell Lymphoma (MCL)1
3RecruitingTreatmentMultiple Myeloma (MM)11
3RecruitingTreatmentMyelodysplastic Syndrome1
3RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3RecruitingTreatmentRelapsed or Refractory Systemic Light Chain Amyloidosis1
3RecruitingTreatmentSolitary Osseous Plasmacytoma1
3RecruitingTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3TerminatedTreatmentChronic Lymphocytic Leukaemia (CLL)1
3TerminatedTreatmentMalignant Lymphomas1
3TerminatedTreatmentMantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
3TerminatedTreatmentStage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
3WithdrawnTreatmentBlood Protein Disorders / Hematologic Diseases / Multiple Myeloma (MM) / Neoplasms / Paraproteinemias / Plasma Cells / Therapeutic Uses1
4Active Not RecruitingTreatmentMultiple Myeloma (MM)2
4CompletedTreatmentCutaneous Lupus1
4Not Yet RecruitingTreatmentMultiple Myeloma (MM)1
4TerminatedTreatmentAML1
Not AvailableActive Not RecruitingNot AvailableMultiple Myeloma (MM)1
Not AvailableActive Not RecruitingTreatmentCLL / Leukemias1
Not AvailableActive Not RecruitingTreatmentMultiple Myeloma (MM)1
Not AvailableAvailableNot AvailableMultiple Myeloma (MM)1
Not AvailableAvailableNot AvailableMultiple Myeloma (MM) / Multiple Myeloma in Relapse / Refractory Multiple Myeloma / Relapsed Multiple Myeloma1
Not AvailableCompletedNot AvailableMultiple Myeloma (MM)1
Not AvailableCompletedNot AvailableMyelodysplastic Syndrome1
Not AvailableCompletedTreatmentAcute Myeloid Leukaemias (AML) / Anemias / Dysmyelopoietic Syndromes / Leukemia, Myelocytic, Acute / Leukemias / Myelodysplastic Syndromes (MDS)1
Not AvailableCompletedTreatmentAmyloidosis / Leukemias1
Not AvailableCompletedTreatmentCutaneous Lupus Erythematosus (CLE)1
Not AvailableCompletedTreatmentMultiple Myeloma (MM)1
Not AvailableRecruitingNot AvailableMalignant Lymphomas1
Not AvailableRecruitingNot AvailableMultiple Myeloma (MM)2
Not AvailableRecruitingNot AvailableMyelodysplastic Syndrome / Myelodysplastic Syndromes (MDS)1
Not AvailableRecruitingTreatmentBlood And Marrow Transplantation / Leukemias / Malignant Lymphomas1
Not AvailableTerminatedNot AvailableMultiple Myeloma (MM)1
Not AvailableTerminatedTreatmentB-Cell Chronic Lymphocytic Leukemia / Chronic Lymphocytic Leukaemia (CLL) / Stage 0 Chronic Lymphocytic Leukemia / Stage I Chronic Lymphocytic Leukemia / Stage II Chronic Lymphocytic Leukemia1
Not AvailableTerminatedTreatmentPlasma Cell Myeloma1
Pharmacoeconomics
Manufacturers
  • Celgene corp
  • Celgene Corporation
Packagers
Dosage forms
FormRouteStrength
CapsuleOral10 mg/1
CapsuleOral10 mg
CapsuleOral15 mg/1
CapsuleOral15 mg
CapsuleOral2.5 mg/1
CapsuleOral2.5 mg
CapsuleOral20 mg/1
CapsuleOral20 mg
CapsuleOral25 mg
CapsuleOral25 mg/1
CapsuleOral5 mg
CapsuleOral5 mg/1
CapsuleOral7.5 mg
Prices
Unit descriptionCostUnit
Revlimid 25 mg capsule411.71USD capsule
Revlimid 15 mg capsule407.7USD capsule
Revlimid 10 mg capsule406.05USD capsule
Revlimid 5 mg capsule388.0USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2342974 No2005-08-162014-02-24Canada
CA2477301 No2009-09-012023-04-13Canada
US5635517 No1999-10-042019-10-04Us
US6045501 No1998-08-282018-08-28Us
US6281230 No1996-07-242016-07-24Us
US6315720 No2000-10-232020-10-23Us
US6555554 No1996-07-242016-07-24Us
US6561976 No1998-08-282018-08-28Us
US6561977 No2000-10-232020-10-23Us
US6755784 No2000-10-232020-10-23Us
US6908432 No1998-08-282018-08-28Us
US7119106 No1996-07-242016-07-24Us
US7189740 No2003-04-112023-04-11Us
US7465800 No2007-04-272027-04-27Us
US7468363 No2003-10-072023-10-07Us
US7855217 No2004-11-242024-11-24Us
US7968569 No2003-10-072023-10-07Us
US8204763 No1998-08-282018-08-28Us
US8288415 No1996-07-242016-07-24Us
US8315886 No2000-10-232020-10-23Us
US8404717 No2003-04-112023-04-11Us
US8530498 No2003-05-152023-05-15Us
US8589188 No1998-08-282018-08-28Us
US8626531 No2000-10-232020-10-23Us
US8648095 No2003-05-152023-05-15Us
US8741929 No2008-03-082028-03-08Us
US9056120 No2003-04-112023-04-11Us
US9101621 No2003-05-152023-05-15Us
US9101622 No2003-05-152023-05-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySoluble in organic solvent/water mixtures, and buffered aqueous solvents. Lenalidomide is more soluble in organic solvents and low pH solutions. Solubility was significantly lower in less acidic buffers, ranging from about 0.4 to 0.5 mg/mL.Not Available
logP-0.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.33 mg/mLALOGPS
logP-0.43ALOGPS
logP-0.71ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)11.61ChemAxon
pKa (Strongest Basic)2.31ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.5 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity68.3 m3·mol-1ChemAxon
Polarizability25.55 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9958
Blood Brain Barrier+0.9372
Caco-2 permeable-0.5981
P-glycoprotein substrateSubstrate0.6845
P-glycoprotein inhibitor IInhibitor0.6012
P-glycoprotein inhibitor IINon-inhibitor0.8927
Renal organic cation transporterNon-inhibitor0.726
CYP450 2C9 substrateNon-substrate0.8861
CYP450 2D6 substrateNon-substrate0.7878
CYP450 3A4 substrateSubstrate0.5855
CYP450 1A2 substrateNon-inhibitor0.8746
CYP450 2C9 inhibitorNon-inhibitor0.8405
CYP450 2D6 inhibitorNon-inhibitor0.8806
CYP450 2C19 inhibitorNon-inhibitor0.78
CYP450 3A4 inhibitorNon-inhibitor0.7469
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.843
Ames testNon AMES toxic0.8268
CarcinogenicityNon-carcinogens0.9068
BiodegradationNot ready biodegradable0.9967
Rat acute toxicity2.5145 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9803
hERG inhibition (predictor II)Non-inhibitor0.5098
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-0002-1920000000-c10c48acd9b8123e3505View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-qTof , PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as isoindolones. These are aromatic polycyclic compounds that an isoindole bearing a ketone.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsoindoles and derivatives
Sub ClassIsoindolines
Direct ParentIsoindolones
Alternative ParentsAlpha amino acids and derivatives / Isoindoles / Piperidinediones / Delta lactams / Benzenoids / Tertiary carboxylic acid amides / N-unsubstituted carboxylic acid imides / Dicarboximides / Azacyclic compounds / Primary amines
SubstituentsAlpha-amino acid or derivatives / Isoindolone / Isoindole / Piperidinedione / Delta-lactam / Piperidinone / Piperidine / Benzenoid / Carboxylic acid imide / Dicarboximide
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorsdicarboximide, aromatic amine, piperidones, isoindoles (CHEBI:63791 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Normal degradation of key regulatory proteins is required for normal limb outgrowth and expression of the fibroblast growth factor FGF8. May play a role in memory and learning by regulating the assembly an...
Gene Name:
CRBN
Uniprot ID:
Q96SW2
Uniprot Name:
Protein cereblon
Molecular Weight:
50545.375 Da
References
  1. Zhu YX, Kortuem KM, Stewart AK: Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54(4):683-7. doi: 10.3109/10428194.2012.728597. Epub 2012 Sep 28. [PubMed:22966948 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Tumor necrosis factor receptor superfamily binding
Specific Function:
Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced b...
Gene Name:
TNFSF11
Uniprot ID:
O14788
Uniprot Name:
Tumor necrosis factor ligand superfamily member 11
Molecular Weight:
35477.81 Da
References
  1. Akobeng AK, Stokkers PC: Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351. doi: 10.1002/14651858.CD007351.pub2. [PubMed:19370685 ]
  2. Melchert M, List A: The thalidomide saga. Int J Biochem Cell Biol. 2007;39(7-8):1489-99. Epub 2007 Jan 30. [PubMed:17369076 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor binding
Specific Function:
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. This cadherin may play a important role in endothelial cell biology through control of the cohesion and organization of the intercellular junctions. It associates with alpha-cate...
Gene Name:
CDH5
Uniprot ID:
P33151
Uniprot Name:
Cadherin-5
Molecular Weight:
87527.715 Da
References
  1. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, Schafer PH, Bartlett JB: The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res. 2009 Mar;77(2):78-86. doi: 10.1016/j.mvr.2008.08.003. Epub 2008 Sep 4. [PubMed:18805433 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
negative modulator
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Uniprot Name:
Prostaglandin G/H synthase 2
Molecular Weight:
68995.625 Da
References
  1. Payvandi F, Wu L, Haley M, Schafer PH, Zhang LH, Chen RS, Muller GW, Stirling DI: Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol. 2004 Aug;230(2):81-8. [PubMed:15598423 ]
  2. Zeldis JB, Schafer PH, Bennett BL, Mercurio F, Stirling DI: Potential new therapeutics for Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr;30(2):275-81. [PubMed:12720152 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Uniprot Name:
Multidrug resistance protein 1
Molecular Weight:
141477.255 Da
Drug created on June 13, 2005 07:24 / Updated on July 27, 2017 16:00